Welcome to the e-CCO Library!

P550: Anti-mycobacterium paratuberculous therapy in Crohn’s disease: outcomes from tertiary IBD referral centres
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Johnston*1, S. Honap1, B. Al-Hakim1, J. Sanderson1

Created: Friday, 22 February 2019, 9:41 AM
P550: Characterisation of hospitalised patients with ulcerative colitis treated with tofacitinib in the OCTAVE clinical programme for up to 7.8 years
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Taxonera, C.(1)*;Ha, C.(2);del Pilar Fortes, M.(3);Gardiner, S.(3);Mundayat, R.(3);Ghosh, S.(4);Connor, S.J.(5);
Created: Friday, 14 July 2023, 11:05 AM
P550: Clinical features of demyelination following anti-TNFα therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hendy P.1,2, Heerasing N.*1,2, Walker G.2, Heap G.1,2, Bewshae C.2, Kennedy N.1, Goodhand J.1, Martin R.3, Hobart J.4, Harrower T.5, Coles A.6, Ahmad T.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P550: Early 12-week ultrasound response to treatment, used as a predictor of response at 6 months in Crohn’s disease: A prospective cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Halasz1*, C. Lu1, G. Kaplan1,2, D. Tanyingoh2, C. Seow1, R. Panaccione1, S. Devlin1, S. Wilson3, K. Novak1

Created: Thursday, 21 February 2019, 9:14 AM
P550: Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU
Year: 2022
Source: ECCO'22
Authors: Chaparro, M.(1); G Donday, M.(1);Rubio, S.(2);Nuñez, A.(3);Calviño Suarez, C.(4);Madero, L.(5);Figueira, M.(6);Rivero, M.(7);Pérez Martínez, I.(8);Diz-Lois Palomares, M.T.(9);Huguet, J.M.(10);Marín Pedrosa, S.(11);Aguas, M.(12);Arroyo, M.(13);Ruiz-Cerulla, A.(14);Vázquez Morón, J.M.(15);Fernández-Clotet, A.(16);Guerra, I.(17);López Serrano, P.(18);Rodríguez-Lago, I.(19);Arias García, L.(20);Camargo Camero, R.(21);Casanova, M.J.(1);Martínez Montiel, P.(22);Sendra Rumbeu, P.(23);Suarez Ferrer, C.(24);Valldosera Gomis, G.(25);Armesto, R.(26);Bujanda, L.(27);Calvo Moya, M.(28);Hervías Cruz, D.(29);Robles Alonso, V.(30);de Jorge Turrión, M.Á.(31);Zúñiga de Mora-Figueroa, B.(32);Molina Arriero, G.(33);Acosta, D.(34);Brenes, Y.(34);Hermida, S.(34);Parra, P.(34);Gisbert, J.P.(1);
Created: Friday, 11 February 2022, 3:56 PM
P550: Short term effects of a combined lifestyle intervention in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Lamers, C.R.(1,2);de Roos, N.M.(2);Heerink, H.H.(3);van de Worp - Kalter, L.A.(4);Witteman, B.J.M.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P551 Combination therapy in IBD Patients: Do we need to maximise the dose of Azathioprine?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Arieira1,2,3, F. Dias de Castro1,2,3, T. Cúrdia Gonçalves1,2,3, M.J. Moreira1,2,3, J. Cotter1,2,3

Created: Thursday, 30 January 2020, 10:12 AM
P551: 6-Thioguanine nucleotide levels are associated with mucosal healing in patients with Crohn’s disease: A multi-centre, international study
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Mao1, J. Guo1, R. Luber2, B.-l. Chen1, Y. He1, Z.-r. Zeng1, S. Ben-Horin3, M. Sparrow2, R. Xavier4, M.-h. Chen1*

Created: Thursday, 21 February 2019, 9:14 AM
P551: Lack of adherence to infliximab in inflammatory bowel disease patients contributes to loss of response in Crohn’s disease.
Year: 2021
Source: ECCO'21 Virtual
Authors: Ferreiro Iglesias, R.(1);Gonzalez-Lopez, J.(2);Calvino-Suarez, C.(1);Mauriz-Barreiro, V.(1);Baston-Rey, I.(1);Cruz, R.(3);Dominguez-Munoz, J.E.(1);Barreiro-de Acosta, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P551: Platelet-to-lymphocyte ratio index for non-invasive assessment of endoscopic activity in small bowel Crohn's disease: application and prospective validation.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Macedo Silva, V.(1)*;Ferreira, A.I.(1);Lima Capela, T.(1);Arieira, C.(1);Cúrdia Gonçalves, T.(1);Boal Carvalho, P.(1);Dias de Castro, F.(1);Moreira, M.J.(1);Cotter, J.(1);
Created: Friday, 14 July 2023, 11:05 AM
P551: Safety and effectiveness of vedolizumab for the treatment of paediatric patients with Inflammatory Bowel Diseases
Year: 2022
Source: ECCO'22
Authors: Fabiszewska, S.(1);Derda, E.(1);Szymańska, E.(1);Osiecki, M.(1);Kierkuś, J.(1);
Created: Friday, 11 February 2022, 3:56 PM
P551: Smooth Seton® for perianal fistulas: a knot-less solution
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Stellingwerf M.*1, de Groof J.1, Buskens C.1, Nerkens W.2, Horeman T.2, Bemelman W.1

Created: Wednesday, 20 February 2019, 10:36 AM
P551: Use of preoperative total parenteral nutrition is associated with clinical and laboratory remission in severe active Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Kolonimos*1,2, M. S. Berns1,2, L. Hai Katvan1,2, M. Zelcer1,2, O. A. Hatoum2,3, N. Sakran2,3, I. M. Gralnek1,2, E. Zittan1,2

Created: Friday, 22 February 2019, 9:41 AM
P552 Withdrawal of immunomodulator medications (IM) in children with inflammatory bowel disease on combination therapy of IM and biologics
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Chandrakumar1, M. Carroll2, J. deBruyn3, K. Jacobson4, H. Huynh2, E. Wine2, S. Lawrence4, W. El-Matary5

Created: Thursday, 30 January 2020, 10:12 AM
P552: An online educational portal improves concerns of inflammatory bowel disease patients regarding pregnancy and medication
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sutton R.1, Wierstra K.2, Ambrosio L.3, Dieleman L.3, Fedorak R.N.3, Halloran B.3, Kroeker K.I.3, Wong K.3, Berga K.-A.4, Huang V.W.*5

Created: Wednesday, 20 February 2019, 10:36 AM
P552: Anti-TNF Treatment and Risk of Atrial Fibrillation in Inflammatory Bowel Disease Patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cohen, Y.(1);Fischman, M.(1);Waterman, M.(2);Dolnikov, K.(3);Azzam, Z.S.(3);Ghersin, I.(2)*;
Created: Friday, 14 July 2023, 11:05 AM
P552: Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort.
Year: 2021
Source: ECCO'21 Virtual
Authors: Xiao, Y.(1);AL Khoury, A.(2);Golovics, P.(3);Kohen, R.(2);Afif, W.(2);Wild, G.(2);Friedman, G.(4);Galiatsatos, P.(4);Hilzenrat, N.(4);Szilagyi, A.(4);Wyse, J.(4);Cohen, A.(4);Bitton, A.(4);Bessissow, T.(4);Lakatos, P.L.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P552: Early use of vedolizumab vs. infliximab in biologic-naive patients with ulcerative colitis: A real-world analysis of healthcare utilisation
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Patel1*, J.M. Khalid1, S. Shah2, R. Shah3, A. Berger2

Created: Thursday, 21 February 2019, 9:14 AM
P552: Gastroenterologists’ perceptions on use of medical cannabis for IBD
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Koslowsky*1, A. Bar-Gil Shitrit1, E. Goldin1, B. Mazuz1

Created: Friday, 22 February 2019, 9:41 AM
P552: Higher Serum Ustekinumab Levels Correlate With Higher Rates Of Steroid-Free Deep Remission And Endoscopic Healing In Patients With Inflammatory Bowel Diseases
Year: 2022
Source: ECCO'22
Authors: Yarur, A.(1);Ungaro, R.(2);Jain, A.(3);Nunex, L.(1);Spencer, E.(2);Bruss, A.(1);Berens, B.(1);Beniwal-Patel, P.(1);Dervieux, T.(3);Dubinsky, M.(2);
Created: Friday, 11 February 2022, 3:56 PM